Contact this trialFirst, we need to learn more about you.
Janus Kinase (JAK) Inhibitor
Upadacitinib for Prurigo Nodularis
Recruiting3 awardsPhase 4
East Windsor, New Jersey
This trial will involve 25 participants with moderate-to-severe prurigo nodularis who will be given upadacitinib for 24 weeks.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service